Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PRPS1 | P60891 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.35 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707575 | 0.85 | PRKAB2 (0.38) | MEN1KMT2A | |
| SCHEMBL2136589 | 0.84 | TSHR (0.42) | KDM4ELMNASLC6A3 | |
| SCHEMBL657770 | 0.74 | LMNA (0.41) | LMNANPSR1SLC6A3 | |
| SCHEMBL2136186 | 0.74 | AHR (0.45) | — | |
| SCHEMBL2136080 | 0.74 | ALOX15 (0.41) | — | |
| SCHEMBL4150950 | 0.70 | HSP90AA1 (0.44) | KDM4EPRPS1MEN1KMT2ANPSR1 | |
| SCHEMBL24233561 | 0.69 | MEN1 (0.43) | FUCA1KDM4EPRPS1MEN1KMT2A | |
| SCHEMBL29274944 | 0.69 | FUCA1 (0.36) | FUCA1KDM4ENPSR1SLC6A3 | |
| SCHEMBL19315241 | 0.69 | PARP1 (0.44) | PRPS1MEN1KMT2A | |
| SCHEMBL26998904 | 0.68 | DAO (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2447265-A1 | NOVEL THIOPHENE CARBOXAMIDE DERIVATIVE AND MEDICINAL USE OF SAME | Sanwa Kagaku Kenkyusho Co., Ltd (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101137-A1 | NOVEL THIOPHENECARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | GCK, GCKR, HK2 | FUCA1 737/4885RXFP1 1845/4885KDM4E 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.